REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)

News

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
Regeneron Announces Investor Conference Presentations
1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky [Yahoo! Finance]
Regeneron Pharmaceuticals (REGN) Announces Collaboration With Telix Pharmaceuticals Limited [Yahoo! Finance]
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com